TMCnet News
Research and Markets: PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 for the $10 Billion IndustryDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/7vck6x/pharmapoint) has announced the addition of the "PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023" report to their offering. The 2013 base-year market sales for asthma pharmaceuticals in the US were around $10.1 billion As in the global market, this growth will be fueled mainly by the uptake of the new branded biologic drugs. A dip in sales caused by the Singulair patent expiry in 2012, as well as the patent expiry of numerous SABA, ICS, and ICS/LABA products over the forecast period, will be offset by eight pipeline product launches, seven of which are targeted biologics. Scope - Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficay profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the US Asthma market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
8 Market Outlook
9 Appendix For more information visit http://www.researchandmarkets.com/research/7vck6x/pharmapoint
|